Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is developing a two-pronged approach to address major neurological disorders, focusing on multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company's pipeline includes Lucid-MS, a patented new chemical entity for MS, and unbuzzd, a dietary supplement designed to support alcohol metabolism and reduce hangover symptoms.
Multiple sclerosis affects an estimated 2.9 million people worldwide, with about one million cases in the United States. Current therapies often fall short, leaving patients with limited options. Lucid-MS takes a fundamentally different approach from existing treatments, and its phase 2 development is supported by an ongoing imaging collaboration with Massachusetts General Hospital. This partnership aims to provide deeper insights into the drug's mechanism and efficacy.
In addition to MS, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement that supports alcohol metabolism and reduces the acute effects of intoxication and hangover. This product addresses a common but often overlooked area of neurological health, offering a potential solution for millions who experience cognitive and physiological impairments due to alcohol consumption.
The company's efforts are particularly significant given the high prevalence and debilitating nature of these conditions. Neurological disorders affect hundreds of millions globally, and for many patients, existing treatments provide insufficient relief. By targeting both chronic and acute neurological issues, Quantum BioPharma is positioning itself to make a meaningful impact on public health.
Investors can find the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM.
